PubMed Health⌕ Search

Biomedical subjects

P A Wilkinson

Publications and source records attributed to P A Wilkinson.

17 recordsLinked to original sources
PubMed1991

Mortality and morbidity of prostatectomy. How far does preselection and pre-operative care influence the result?

Mortality and morbidity rates of prostatectomy have been progressively reduced over the past years, but with increasing ageing of the population, a limit is reached when medical complicating factors ensue, beyond which operative intervention carries an unacceptable risk. Results of surgery have little meaning if patients who are not fit or too old are excluded and not shown. It is with the above objectives in view that a prospective study is reported where all patients who presented or were admitted with prostatic symptoms over 1 year were recorded. There were 246 patients. Age, presentation and ASA (American Society of Anesthesiologists) status, post-operative problems and stay were noted. Joint assessment with a senior anaesthetist was performed in all higher-risk patients. 132 patients were operated on, 91% by transurethral resection of the prostate. 66% were ASA 2 and 3. Age itself bore no relation to length of post-operative stay but ASA status did. There was no mortality. However, 12 (9%) ASA 4 cases were excluded from surgery. It is concluded that with careful assessment, patients who are old and medically compromised can undergo prostatectomy safely, but one has to identify accurately those unsuitable for surgery and offer alternative treatment.

Age Factors↗
PubMed1988

Epidural fentanyl and monoamine oxidase inhibitors.

The successful use of continuous epidural fentanyl infusion to control postoperative pain in a patient treated with monoamine oxidase inhibitors is described. The use of epidural opioids may be a safe technique for the management of such patients.

Aged↗
PubMed1970

Occurrence of an abnormal lipoprotein in patients with liver disease.

An abnormal lipoprotein, containing a high proportion of unesterified cholesterol and phospholipid, has previously been described as occurring in the serum of patients with obstructive jaundice, and has been called lipoprotein X. Using an immunoelectrophoretic method for the detection of lipoprotein X in serum, the sera of 97 patients with liver disease have been screened and the associated biochemical features measured.Lipoprotein X was found in 45% of cases of liver disease with cholestatic features, and was not detected in cases of liver disease without cholestasis. The incidence of lipoprotein X in different causes of cholestatis varied, and while it was commonest in cases of extrahepatic obstruction of recent onset, occurring in 75% of cases, it was also found in primary biliary cirrhosis in 48% of cases, and in cholestatic hepatitis, less commonly.The cause of the appearance of lipoprotein X is unknown, but analysis of associated biochemical features suggested a relationship to physical biliary obstruction rather than a derangement of liver cell function.

Alkaline Phosphatase↗
PubMedDate not supplied

Plasma concentrations and relative bioavailability of naftidrofuryl from different salt forms.

The relative bioavailability of the vasodilator naftidrofuryl from formulations containing its oxalate or citrate salt has been estimated using a specific HPLC assay, and a less specific fluorimetric assay, to measure plasma drug concentrations. The conclusions of the study were the same irrespective of the assay employed. The relative rate, but not the extent, of bioavailability of naftidrofuryl from the citrate salt (peak 1096 ng ml-1 at 0.76 h) was marginally greater (p = 0.003) than that from the oxalate salt (peak 922 ng ml-1 at 0.94 h). The degree of intersubject variability was similar after administration of either salt form. The mean half-life of naftidrofuryl was 1.8 h and its mean residence time was 2.5 h.

Adult↗